Immunome to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of leading and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in an informal meeting at Morgan Stanley’s 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 p.m. Eastern Time.

Interested parties may access the live audio webcast for this conference call via the Investor Relations section of the Company’s website at www.immunome.com. The replay of the webcast will be available following the live presentation for approximately 30 days.